CN1688582A - 稠合吡咯-嘧啶衍生物 - Google Patents

稠合吡咯-嘧啶衍生物 Download PDF

Info

Publication number
CN1688582A
CN1688582A CNA038233673A CN03823367A CN1688582A CN 1688582 A CN1688582 A CN 1688582A CN A038233673 A CNA038233673 A CN A038233673A CN 03823367 A CN03823367 A CN 03823367A CN 1688582 A CN1688582 A CN 1688582A
Authority
CN
China
Prior art keywords
alkyl
amino
optional
replaces
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CNA038233673A
Other languages
English (en)
Chinese (zh)
Other versions
CN100384846C (zh
Inventor
M·施马达
T·穆拉塔
K·富基卡米
H·楚吉施塔
N·奥莫里
I·卡托
M·缪拉
K·乌尔巴恩斯
F·甘特纳
K·巴康
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Bayer Intellectual Property GmbH
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of CN1688582A publication Critical patent/CN1688582A/zh
Application granted granted Critical
Publication of CN100384846C publication Critical patent/CN100384846C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CNB038233673A 2002-09-30 2003-09-18 稠合吡咯-嘧啶衍生物 Expired - Lifetime CN100384846C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02021861 2002-09-30
EP02021861.6 2002-09-30

Publications (2)

Publication Number Publication Date
CN1688582A true CN1688582A (zh) 2005-10-26
CN100384846C CN100384846C (zh) 2008-04-30

Family

ID=32039115

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038233673A Expired - Lifetime CN100384846C (zh) 2002-09-30 2003-09-18 稠合吡咯-嘧啶衍生物

Country Status (33)

Country Link
US (2) US7511041B2 (und)
EP (2) EP1549652B1 (und)
JP (1) JP4790266B2 (und)
KR (1) KR101059652B1 (und)
CN (1) CN100384846C (und)
AR (2) AR041426A1 (und)
AT (2) ATE411996T1 (und)
AU (1) AU2003293310B2 (und)
BR (1) BRPI0314830B8 (und)
CA (1) CA2499134C (und)
CY (2) CY1109790T1 (und)
DE (1) DE60324296D1 (und)
DK (2) DK2042504T3 (und)
EC (2) ECSP055768A (und)
ES (2) ES2367141T3 (und)
HK (1) HK1084393A1 (und)
HR (2) HRP20050375B1 (und)
IL (1) IL166855A (und)
MA (1) MA27483A1 (und)
MX (1) MXPA05001808A (und)
MY (1) MY140756A (und)
NO (1) NO331457B1 (und)
NZ (1) NZ539062A (und)
PE (1) PE20050089A1 (und)
PL (1) PL226562B1 (und)
PT (2) PT2042504E (und)
RU (1) RU2326881C9 (und)
SI (2) SI1549652T1 (und)
TW (1) TWI327570B (und)
UA (1) UA82205C2 (und)
UY (1) UY28001A1 (und)
WO (1) WO2004029055A1 (und)
ZA (1) ZA200503306B (und)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101990577A (zh) * 2007-09-19 2011-03-23 波士顿大学理事会 鉴定肺病药物开发的新途径
CN102459253A (zh) * 2009-04-30 2012-05-16 葛兰素集团有限公司 作为pi3-激酶抑制剂的*唑取代的吲唑化合物
CN103339133A (zh) * 2010-11-11 2013-10-02 拜耳知识产权有限责任公司 烷氧基取代的2,3-二氢咪唑并[1,2-c]喹唑啉
CN103370320A (zh) * 2010-11-11 2013-10-23 拜耳知识产权有限责任公司 芳基氨基醇取代的2,3-二氢咪唑并[1,2-c]喹啉
CN103649091A (zh) * 2011-04-05 2014-03-19 拜耳知识产权有限责任公司 取代的2,3-二氢咪唑并[1,2-c]喹唑啉盐
CN105130997A (zh) * 2015-09-25 2015-12-09 苏州明锐医药科技有限公司 一种库潘尼西的制备方法
CN105130998A (zh) * 2015-09-25 2015-12-09 苏州立新制药有限公司 库潘尼西的制备方法
CN107074776A (zh) * 2014-11-07 2017-08-18 拜耳制药股份公司 Copanlisib及其二盐酸盐的合成
US9920374B2 (en) 2005-04-14 2018-03-20 Trustees Of Boston University Diagnostic for lung disorders using class prediction
CN108774232A (zh) * 2006-12-05 2018-11-09 拜耳知识产权有限责任公司 2,3-二氢咪唑并[1,2-c]喹唑啉取代衍生物
CN109053554A (zh) * 2018-08-01 2018-12-21 江苏八巨药业有限公司 一种使用高效催化剂合成3-乙酰吡啶的方法
US10526655B2 (en) 2013-03-14 2020-01-07 Veracyte, Inc. Methods for evaluating COPD status
WO2020020385A1 (zh) * 2018-07-27 2020-01-30 上海翰森生物医药科技有限公司 含三并环类衍生物抑制剂、其制备方法和应用
CN111247152A (zh) * 2017-09-20 2020-06-05 璧辰医药技术股份有限公司 作为激酶抑制剂的环状亚氨基嘧啶衍生物
US10731223B2 (en) 2009-12-09 2020-08-04 Veracyte, Inc. Algorithms for disease diagnostics
CN114621236A (zh) * 2022-04-25 2022-06-14 河南湾流生物科技有限公司 一种喹啉类饲料添加剂的制备方法
US11639527B2 (en) 2014-11-05 2023-05-02 Veracyte, Inc. Methods for nucleic acid sequencing
US11977076B2 (en) 2006-03-09 2024-05-07 Trustees Of Boston University Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
US12110554B2 (en) 2009-05-07 2024-10-08 Veracyte, Inc. Methods for classification of tissue samples as positive or negative for cancer
US12297505B2 (en) 2014-07-14 2025-05-13 Veracyte, Inc. Algorithms for disease diagnostics
US12305238B2 (en) 2008-11-17 2025-05-20 Veracyte, Inc. Methods for treatment of thyroid cancer

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
AU2004268104B9 (en) * 2003-08-29 2009-03-26 Mitsui Chemicals, Inc. Insecticide for agricultural or horticultural use and method of use thereof
ES2605792T3 (es) 2004-05-13 2017-03-16 Icos Corporation Quinazolinona usada como inhibidor de la fosfatidilinositol 3-quinasa delta humana
KR20070064660A (ko) 2004-10-07 2007-06-21 베링거 인겔하임 인터내셔날 게엠베하 Pi3 키나제
WO2006040645A1 (en) * 2004-10-11 2006-04-20 Ranbaxy Laboratories Limited N-(3,5-dichloropyridin-4-yl)-2,4,5-alkoxy and 2,3,4-alkoxy benzamide derivatives as pde-iv (phophodiesterase type-iv) inhibitors for the treatment of inflammatory diseases such as asthma
BRPI0614188A2 (pt) * 2005-07-29 2011-03-15 4Sc Ag compostos inibidores heterocìclicos de nf-kappab, uso dos mesmos e composição farmacêutica
US7517995B2 (en) * 2006-04-06 2009-04-14 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-cyclopentapyrazole
US7691868B2 (en) 2006-04-06 2010-04-06 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-quinazoline
TWI498332B (zh) * 2006-04-26 2015-09-01 Hoffmann La Roche 作為pi3k抑制劑之嘧啶衍生物及相關製備方法、醫藥組合物、用途、套組及產物
WO2008064244A2 (en) * 2006-11-20 2008-05-29 The Trustees Of Columbia University In The City Of New York Phosphoinositide modulation for the treatment of neurodegenerative diseases
EP1953163A1 (en) 2007-02-01 2008-08-06 Boehringer Ingelheim Pharma GmbH & Co. KG Pteridinone derivatives as PI3-kinases inhibitors
WO2008148023A2 (en) * 2007-05-23 2008-12-04 Medical College Of Georgia Research Institute, Inc. Compositions and methods for treating neurological disorders
EP2217590A4 (en) * 2007-09-17 2011-12-14 Glaxosmithkline Llc Pyridopyrimidine derivatives as PI3-kinase inhibitors
US8859572B2 (en) * 2008-01-14 2014-10-14 Bayer Intellectual Property Gmbh Sulfone substituted 2,3-dihydroimidazo [1,2-C] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis
US9029411B2 (en) 2008-01-25 2015-05-12 Millennium Pharmaceuticals, Inc. Thiophenes and uses thereof
US20090227575A1 (en) * 2008-03-04 2009-09-10 Wyeth 7H-PYRROLO[2,3-H]QUINAZOLINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESIS
EP2444403A1 (en) * 2008-04-18 2012-04-25 Shionogi Co., Ltd. Heterocyclic compound having inhibitory activity on PI3K
US20110212053A1 (en) * 2008-06-19 2011-09-01 Dapeng Qian Phosphatidylinositol 3 kinase inhibitors
EP2168582A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Combinations of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
US8791131B2 (en) * 2008-09-30 2014-07-29 Pfizer Inc. Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions
ES2443127T3 (es) * 2008-11-11 2014-02-17 Jeil Pharmaceutical Co., Ltd. Nuevos derivados tricíclicos o sales de éstos farmacéuticamente aceptables, su procedimiento de fabricación y composiciones farmacéuticas que los contienen
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
PT2355828T (pt) 2008-11-13 2018-07-02 Gilead Calistoga Llc Terapias para malignidades hematológicas
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
CN102395585A (zh) * 2009-01-30 2012-03-28 米伦纽姆医药公司 杂芳基化合物和其作为pi3k抑制剂的用途
KR20120002995A (ko) 2009-03-24 2012-01-09 길리아드 칼리스토가 엘엘씨 2―퓨리닐―3―톨릴―퀴나졸리논 유도체의 회전장애 이성질체 및 사용 방법
ES2548253T3 (es) 2009-04-20 2015-10-15 Gilead Calistoga Llc Métodos para el tratamiento de tumores sólidos
CN102647987A (zh) 2009-07-21 2012-08-22 吉里德卡利斯托加公司 使用pi3k抑制剂治疗肝脏障碍
NZ626650A (en) * 2009-09-09 2015-12-24 Celgene Avilomics Res Inc Pi3 kinase inhibitors and uses thereof
WO2011128407A2 (en) * 2010-04-16 2011-10-20 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
US9062038B2 (en) 2010-08-11 2015-06-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
PE20140165A1 (es) 2010-10-01 2014-02-26 Bayer Ip Gmbh Combinaciones que contienen n-(2-arilamino)arilsulfonamida
UA113280C2 (xx) * 2010-11-11 2017-01-10 АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
JO3733B1 (ar) 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
US8865730B2 (en) 2012-03-05 2014-10-21 Gilead Calistoga Llc Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
US20160143910A1 (en) 2013-03-15 2016-05-26 Constellation Pharmaceuticals, Inc. Methods of treating cancer and preventing cancer drug resistance
EP2983669B1 (en) 2013-04-08 2018-10-24 Bayer Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas
PE20200447A1 (es) 2013-05-01 2020-02-28 Hoffmann La Roche Compuestos de biheteroarilo y usos de los mismos
WO2015027431A1 (en) 2013-08-29 2015-03-05 Merck Sharp & Dohme Corp. 2,2-difluorodioxolo a2a receptor antagonists
US9708327B2 (en) 2013-12-20 2017-07-18 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
PT3083630T (pt) 2013-12-20 2019-11-15 Gilead Calistoga Llc Procedimentos para inibidores da fosfatidilinositol 3-quinase
CA2952012A1 (en) 2014-06-13 2015-12-17 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
EP3018127A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
MX2017011635A (es) 2015-03-09 2018-02-09 Bayer Pharma AG Combinaciones que contienen 2,3-dihidroimidazo[1,2-c]quinazolina sustituida.
CA3016584A1 (en) * 2016-03-08 2017-09-14 Bayer Pharma Aktiengesellschaft 2-amino-n-[7-methoxy-2,3-dihydroimidazo-[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamides
EP3219329A1 (en) 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinations of copanlisib
US10927417B2 (en) 2016-07-08 2021-02-23 Trustees Of Boston University Gene expression-based biomarker for the detection and monitoring of bronchial premalignant lesions
EP3515911A1 (en) 2016-09-23 2019-07-31 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
JP2020503289A (ja) 2016-12-14 2020-01-30 ターベダ セラピューティクス インコーポレイテッドTarveda Therapeutics,Inc. Hsp90標的化コンジュゲート及びその製剤
CA3054249A1 (en) 2017-02-24 2018-08-30 Bayer Pharma Aktiengesellschaft Combinations of copanlisib with anti-pd-1 antibody
CA3068324A1 (en) 2017-06-28 2019-01-03 Bayer Consumer Care Ag Combination of a pi3k-inhibitor with an androgen receptor antagonist
EP3498266A1 (en) 2017-12-15 2019-06-19 Bayer Consumer Care AG Formulations of copanlisib
MA50068B1 (fr) 2017-09-08 2024-07-31 Bayer Pharma Aktiengesellschaft Formulations de copanlisib
US11351156B2 (en) 2017-10-13 2022-06-07 Inserm Combination treatment of pancreatic cancer
WO2019101871A1 (en) 2017-11-23 2019-05-31 Inserm (Institut National De La Sante Et De La Recherche Medicale) A new marker for predicting the sensitivity to pi3k inhibitors
WO2019105734A1 (en) 2017-11-28 2019-06-06 Bayer Consumer Care Ag Combinations of copanlisib
WO2019105835A1 (en) 2017-11-29 2019-06-06 Bayer Consumer Care Ag Combinations of copanlisib and anetumab ravtansine
WO2019197269A1 (en) 2018-04-11 2019-10-17 Bayer Aktiengesellschaft Combinations of copanlisib with triazolone derivatives and their use in the treatment of cancer
US20210187134A1 (en) 2018-08-28 2021-06-24 Bayer As Combination of pi3k-inhibitors and targeted thorium conjugates
EP3866805A1 (en) 2018-10-16 2021-08-25 Bayer Aktiengesellschaft Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds
US20220033775A1 (en) 2018-11-05 2022-02-03 Iovance Biotherapeutics, Inc. Expansion of tils utilizing akt pathways inhibitors
BR112021011894A2 (pt) 2018-12-21 2021-09-08 Daiichi Sankyo Company, Limited Composição farmacêutica
WO2020164997A1 (en) 2019-02-12 2020-08-20 Bayer Aktiengesellschaft Combination of pi3k-inhibitors
WO2025087879A2 (en) 2023-10-23 2025-05-01 Institut National de la Santé et de la Recherche Médicale Suppressing the pi3kgamma/akt signalling pathway for the treatment of acute myeloid leukemia

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3644354A (en) * 1968-09-16 1972-02-22 Sandoz Ag 5-substituted-2 3-dihydroimidazo(1 2-c)quinazolines
US4287341A (en) 1979-11-01 1981-09-01 Pfizer Inc. Alkoxy-substituted-6-chloro-quinazoline-2,4-diones
NZ234186A (en) * 1989-07-07 1991-10-25 Janssen Pharmaceutica Nv Imidazo quinazolin-one derivatives and pharmaceutical compositions
CN1033644C (zh) * 1993-01-02 1996-12-25 瑞安大药厂股份有限公司 3-取代甲基-2,3-二氢咪唑并[1,2-c]喹唑啉衍生物,其制备与用途
EP0771204A4 (en) 1994-08-12 1999-10-20 Pro Neuron Inc METHOD FOR TREATING SEPSIS OR FLAMMABLE DISEASES WITH OXYPURINE NUCLEOSIDES
JP4431638B2 (ja) * 1996-01-29 2010-03-17 アメリカ合衆国 ジヒドロピリジン―、ピリジン―、ベンゾピラン―オン―およびトリアゾロキナゾリン誘導体、それらの製造およびそれらのアデノシン受容体アンタゴニストとしての用途
US5932584A (en) * 1997-05-06 1999-08-03 National Science Council Optically active 2,3-dihydroimidazo(1,2-C) quinazoline derivatives, the preparation and antihypertensive use thereof
AU5566701A (en) 2000-04-25 2001-11-07 Icos Corp Inhibitors of human phosphatidyl-inositol 3-kinase delta
ATE503743T1 (de) * 2000-04-27 2011-04-15 Astellas Pharma Inc Kondensierte heteroarylderivate

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9920374B2 (en) 2005-04-14 2018-03-20 Trustees Of Boston University Diagnostic for lung disorders using class prediction
US10808285B2 (en) 2005-04-14 2020-10-20 Trustees Of Boston University Diagnostic for lung disorders using class prediction
US11977076B2 (en) 2006-03-09 2024-05-07 Trustees Of Boston University Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells
CN108774232B (zh) * 2006-12-05 2022-08-09 拜耳知识产权有限责任公司 2,3-二氢咪唑并[1,2-c]喹唑啉取代衍生物
CN101631464B (zh) * 2006-12-05 2022-12-06 拜耳知识产权有限责任公司 用于治疗过度增殖疾病和血管发生相关性疾病的2,3-二氢咪唑并[1,2-c]喹唑啉取代衍生物
CN105254634B (zh) * 2006-12-05 2022-05-27 拜耳知识产权有限责任公司 用于治疗过度增殖疾病和血管发生相关性疾病的2,3-二氢咪唑并[1,2-c]喹唑啉取代衍生物
CN108774232A (zh) * 2006-12-05 2018-11-09 拜耳知识产权有限责任公司 2,3-二氢咪唑并[1,2-c]喹唑啉取代衍生物
CN101990577A (zh) * 2007-09-19 2011-03-23 波士顿大学理事会 鉴定肺病药物开发的新途径
US10570454B2 (en) 2007-09-19 2020-02-25 Trustees Of Boston University Methods of identifying individuals at increased risk of lung cancer
US12305238B2 (en) 2008-11-17 2025-05-20 Veracyte, Inc. Methods for treatment of thyroid cancer
CN102459253B (zh) * 2009-04-30 2015-03-25 葛兰素集团有限公司 作为pi3-激酶抑制剂的*唑取代的吲唑化合物
CN102459253A (zh) * 2009-04-30 2012-05-16 葛兰素集团有限公司 作为pi3-激酶抑制剂的*唑取代的吲唑化合物
US12110554B2 (en) 2009-05-07 2024-10-08 Veracyte, Inc. Methods for classification of tissue samples as positive or negative for cancer
US12297503B2 (en) 2009-05-07 2025-05-13 Veracyte, Inc. Methods for classification of tissue samples as positive or negative for cancer
US10731223B2 (en) 2009-12-09 2020-08-04 Veracyte, Inc. Algorithms for disease diagnostics
CN103370320B (zh) * 2010-11-11 2016-04-27 拜耳知识产权有限责任公司 芳基氨基醇取代的2,3-二氢咪唑并[1,2-c]喹啉
CN103339133A (zh) * 2010-11-11 2013-10-02 拜耳知识产权有限责任公司 烷氧基取代的2,3-二氢咪唑并[1,2-c]喹唑啉
CN103370320A (zh) * 2010-11-11 2013-10-23 拜耳知识产权有限责任公司 芳基氨基醇取代的2,3-二氢咪唑并[1,2-c]喹啉
CN103339133B (zh) * 2010-11-11 2016-06-15 拜耳知识产权有限责任公司 烷氧基取代的2,3-二氢咪唑并[1,2-c]喹唑啉
CN103649091B (zh) * 2011-04-05 2016-06-22 拜耳知识产权有限责任公司 取代的2,3-二氢咪唑并[1,2-c]喹唑啉盐
CN103649091A (zh) * 2011-04-05 2014-03-19 拜耳知识产权有限责任公司 取代的2,3-二氢咪唑并[1,2-c]喹唑啉盐
US10526655B2 (en) 2013-03-14 2020-01-07 Veracyte, Inc. Methods for evaluating COPD status
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
US12297505B2 (en) 2014-07-14 2025-05-13 Veracyte, Inc. Algorithms for disease diagnostics
US11639527B2 (en) 2014-11-05 2023-05-02 Veracyte, Inc. Methods for nucleic acid sequencing
CN107074776B (zh) * 2014-11-07 2021-02-02 拜耳制药股份公司 Copanlisib及其二盐酸盐的合成
CN107074776A (zh) * 2014-11-07 2017-08-18 拜耳制药股份公司 Copanlisib及其二盐酸盐的合成
CN105130998A (zh) * 2015-09-25 2015-12-09 苏州立新制药有限公司 库潘尼西的制备方法
WO2017049983A1 (zh) * 2015-09-25 2017-03-30 苏州立新制药有限公司 库潘尼西的制备方法
CN105130997A (zh) * 2015-09-25 2015-12-09 苏州明锐医药科技有限公司 一种库潘尼西的制备方法
CN111247152A (zh) * 2017-09-20 2020-06-05 璧辰医药技术股份有限公司 作为激酶抑制剂的环状亚氨基嘧啶衍生物
WO2020020385A1 (zh) * 2018-07-27 2020-01-30 上海翰森生物医药科技有限公司 含三并环类衍生物抑制剂、其制备方法和应用
CN109053554B (zh) * 2018-08-01 2020-07-28 江苏八巨药业有限公司 一种使用催化剂合成3-乙酰吡啶的方法
CN109053554A (zh) * 2018-08-01 2018-12-21 江苏八巨药业有限公司 一种使用高效催化剂合成3-乙酰吡啶的方法
CN114621236A (zh) * 2022-04-25 2022-06-14 河南湾流生物科技有限公司 一种喹啉类饲料添加剂的制备方法

Also Published As

Publication number Publication date
US20090270388A1 (en) 2009-10-29
NO331457B1 (no) 2012-01-09
EP1549652A1 (en) 2005-07-06
SI2042504T1 (sl) 2011-10-28
ECSP11005768A (es) 2011-03-31
RU2326881C2 (ru) 2008-06-20
AR072458A2 (es) 2010-09-01
KR20050067404A (ko) 2005-07-01
CY1112174T1 (el) 2015-12-09
RU2005113165A (ru) 2005-10-10
CY1109790T1 (el) 2014-09-10
PL226562B1 (pl) 2017-08-31
ATE511510T1 (de) 2011-06-15
AU2003293310A1 (en) 2004-04-19
UA82205C2 (en) 2008-03-25
ZA200503306B (en) 2006-07-26
SI1549652T1 (sl) 2009-04-30
US8129386B2 (en) 2012-03-06
TWI327570B (en) 2010-07-21
DE60324296D1 (de) 2008-12-04
PL375935A1 (en) 2005-12-12
NZ539062A (en) 2007-05-31
EP1549652B1 (en) 2008-10-22
JP2006508063A (ja) 2006-03-09
PE20050089A1 (es) 2005-04-20
ATE411996T1 (de) 2008-11-15
MY140756A (en) 2010-01-15
AU2003293310B2 (en) 2010-04-01
IL166855A (en) 2014-05-28
EP2042504B1 (en) 2011-06-01
PT1549652E (pt) 2008-12-15
HRP20131159B1 (hr) 2019-11-01
HRP20050375A2 (en) 2006-05-31
CN100384846C (zh) 2008-04-30
DK2042504T3 (da) 2011-09-19
ECSP055768A (es) 2005-08-11
PT2042504E (pt) 2011-09-07
HK1084393A1 (en) 2006-07-28
JP4790266B2 (ja) 2011-10-12
BRPI0314830B1 (pt) 2018-03-27
ES2367141T3 (es) 2011-10-28
US7511041B2 (en) 2009-03-31
BRPI0314830B8 (pt) 2021-05-25
RU2326881C9 (ru) 2009-04-10
TW200413379A (en) 2004-08-01
US20060128732A1 (en) 2006-06-15
BR0314830A (pt) 2005-08-16
WO2004029055A1 (en) 2004-04-08
MXPA05001808A (es) 2005-08-16
HRP20131159A2 (hr) 2014-05-23
HRP20050375B1 (hr) 2014-03-14
UY28001A1 (es) 2004-04-30
KR101059652B1 (ko) 2011-08-25
NO20052076L (no) 2005-04-27
AR041426A1 (es) 2005-05-18
MA27483A1 (fr) 2005-08-01
CA2499134C (en) 2011-12-20
ES2312843T3 (es) 2009-03-01
DK1549652T3 (da) 2009-02-23
EP2042504A1 (en) 2009-04-01
CA2499134A1 (en) 2004-04-08

Similar Documents

Publication Publication Date Title
CN1688582A (zh) 稠合吡咯-嘧啶衍生物
CN100343258C (zh) 新的4-氨基-5,6-取代的噻吩并[2,3-d]嘧啶化合物
CN1077107C (zh) 杂环化合物、其制备和用途
CN1171889C (zh) 作为p38蛋白激酶的抑制剂的杂烷基氨基-取代的双环氮杂环类化合物
CN1051548C (zh) 杂双环衍生物、含有它们的药物组合物及其制备方法与用途
CN1275964C (zh) 作为细胞增殖抑制剂的7-氧代吡啶并嘧啶
CN1606444A (zh) 人磷脂酰肌醇3-激酶δ抑制剂
CN1440408A (zh) 人磷脂酰肌醇3-激酶δ的抑制剂
CN1993359A (zh) 杂环取代的环状脲衍生物、其制备及其作为激酶抑制剂的药物用途
CN1070404A (zh) 新的杂环衍生物
CN1626516A (zh) 制备吡唑并嘧啶酮类化合物的新型中间体
CN1867553A (zh) 作为cdk 和/或vegf 抑制剂的氨基亚砜取代的嘧啶化合物、其制备方法以及作为药物的用途
CN1688583A (zh) 用作治疗醛固酮介导的病症的药物的有机化合物
CN1777605A (zh) 大麻素受体配位体及其用途
CN1993129A (zh) 用于药物的噻吩并嘧啶和噻唑并嘧啶
CN1615306A (zh) C-5修饰的吲唑基吡咯并三嗪类化合物
CN1726218A (zh) 吡咯并嘧啶衍生物
CN1714092A (zh) 作为蛋白激酶抑制剂的噻吩并[3,2-b]吡啶-6-腈和噻吩并[2,3-b]吡啶-5-腈
CN1439009A (zh) 咪唑并嘧啶衍生物和三唑并嘧啶衍生物
CN1675225A (zh) 大环嘧啶化合物、其制备方法以及作为药物的应用
CN1633419A (zh) Cdk抑制性嘧啶化合物、其制备方法以及作为药物的应用
CN1761671A (zh) 用作PDE7抑制剂的4-氨基噻吩并[2,3-d]嘧啶-6-甲腈衍生物
CN1711264A (zh) 具有抗癌活性的嘧啶并[4,5-d]嘧啶衍生物
CN1056879A (zh) 吡咯衍生物及其制备方法
CN1307571A (zh) 胍衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1084393

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1084393

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: BAYER SCHERING PHARMACEUTICAL CO., LTD.

Free format text: FORMER OWNER: BAYER PHARMACEUTICAL CO., LTD.

Effective date: 20100420

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: CONNECTICUT STATE, U.S.A TO: BERLIN, GERMANY

TR01 Transfer of patent right

Effective date of registration: 20100420

Address after: Berlin

Patentee after: BAYER SCHERING PHARMA AG

Address before: American Connecticut

Patentee before: Bayer Pharmaceuticals Corp.

ASS Succession or assignment of patent right

Owner name: BAYER INTELLECTUAL PROPERTY GMBH

Free format text: FORMER OWNER: BAYER PHARMACEUTICALS AG

Effective date: 20130322

C41 Transfer of patent application or patent right or utility model
C56 Change in the name or address of the patentee

Owner name: BAYER PHARMACEUTICALS AG

Free format text: FORMER NAME: BAYER SCHERING PHARMA AG

CP01 Change in the name or title of a patent holder

Address after: Berlin

Patentee after: BAYER PHARMA AG

Address before: Berlin

Patentee before: Bayer Schering Pharma AG

TR01 Transfer of patent right

Effective date of registration: 20130322

Address after: German Monheim

Patentee after: BAYER INTELLECTUAL PROPERTY GmbH

Address before: Berlin

Patentee before: BAYER PHARMA AG

CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20080430